Radiopharma for investors
The science, the approved products, the supply bottleneck, and the alpha-emitter pipeline that drives the M&A.
- 1FrontRadiopharmaceuticals & Theranostics
A molecule that homes to the tumour carries a radioactive atom. The same molecule with a different atom lets you see the tumour first.
Why here The front and its constraint: isotope supply.
- 2TermTheranostics
Using the same targeting molecule for a diagnostic scan and a therapy, so you treat exactly what you can see.
Why here The see-then-treat paradigm in one term.
- 3TechnologyStandard of carePSMA PET
A prostate-cancer-specific PET scan that finds spread far earlier than CT or bone scan, and tells you whether a matched radioactive drug will work.
Why here The gatekeeper scan that defines the treatable population.
- 4ProductApprovedLutetium-177 vipivotide tetraxetan
A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.
Why here The best-selling radiopharmaceutical and its label history.
- 5TechnologyApprovedRadioligand therapy (beta emitters)
A drug that finds tumour cells and carries a radioactive atom that irradiates them from inside the body.
Why here How beta emitters work and their limits.
- 6TermAlpha vs beta emitters
Beta particles (lutetium-177) travel millimetres and are good for bulky disease; alpha particles (actinium-225) travel a few cells' width and kill with far higher energy.
Why here Why actinium is the prize.
- 7TechnologyPhase 3Targeted alpha therapy
Like radioligand therapy but with alpha particles: far more destructive over a much shorter range, so single cells can be killed with less collateral damage.
Why here The phase 3 alpha programmes and the supply problem.
- 8CompanyTerraPower Isotopes
Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.
Why here Who is scaling actinium-225.
- 9TargetFAP
FAP is a protein on the scaffolding cells that surround many tumours, so it lights up almost any solid cancer on a PET scan.
Why here The pan-cancer stromal target that could widen the market.
- 10PairingBeta radioligand → alpha radioligand
After lutetium therapy stops working, an actinium version of the same drug can still produce responses.
Why here The sequencing thesis.
- 11RoadmapRadiopharmaceutical roadmap: iodine → lutetium → actinium
The radiopharmaceutical roadmap runs eighty years from radioactive iodine for thyroid cancer to alpha-emitting drugs for prostate and neuroendocrine cancers, with isotope supply as the limiting factor.
Why here The whole arc, historic to speculative.